Multi-site trial of a brief behavioral intervention for dyspnea in patients with advanced lung cancer
Active Grant Awarded
- Award ID
- R01CA292902
- Recipient
-
The General Hospital Corporation UEI FLJ7DQKLL226
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $604,347
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 8% complete
- Place of performance
- Massachusetts, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $604,347 on July 7, 2026, under Grant R01CA292902 from the Cancer Treatment Research program (CFDA 93.395). The award funds a multi-site trial of BREEZE+, a brief behavioral intervention for dyspnea in patients with advanced lung cancer. BREEZE+ builds on BREEZE, a two-session intervention that trained oncology nurses delivered alongside standard oncology visits or by secure video or telephone. BREEZE+ adds a nurse-led booster session and dyspnea management components from a digital health app to reinforce skills and sustain effects. The prior single-center trial showed significant effects at eight weeks that were not sustained at the 24-week follow-up.
Place of performance is Massachusetts, USA, and the ultimate completion date is June 30, 2031. The recipient's Research Management Division administers the award.
The University of Miami, Office of Research Administration - School of Medicine, receives sub-award R01CA292902-GR1005893-S01, dated October 27, 2026, to serve as a study site at the University of Miami Sylvester Comprehensive Cancer Center. Dr. Lara Traeger serves as site Principal Investigator, overseeing IRB approvals and delivery of the BREEZE+ intervention. A University of Miami research assistant identifies eligible patients through chart review, obtains consent, schedules intervention visits, collects participant-reported data, and completes final chart review from the electronic health record.
Description
- Abstract
- Background: dyspnea is one of the most common and debilitating symptoms of advanced lung cancer, with more than 70% of patients reporting marked breathlessness that tends to worsen as the disease progresses. Dyspnea is associated with impaired quality of life, decreased participation in life activities, symptoms of depression and anxiety, increased healthcare utilization, and even desire for death in patients with lung cancer. Unfortunately, limited data support efficacious treatments for dyspnea. Our multidisciplinary team successfully conducted a single-center efficacy trial examining the delivery of a brief, two-session behavioral intervention for dyspnea management in patients with advanced lung cancer, called breeze. Trained oncology nurses administered the intervention to patients in tandem with standard oncology care visits and/or via secure video or telephone to facilitate greater access and participation. We observed significant effects of the intervention on patient-reported dyspnea and functional wellbeing at eight weeks, though these gains were not sustained by the 24-week follow-up timepoint. We now propose to build upon these encouraging findings by conducting a multi- site trial of breeze in a diverse patient population. Moreover, we will enhance the intervention by adding a nurse-led booster session and integrating the dyspnea management components from a digital health APP that our team developed for patients with advanced lung cancer to reinforce breeze's evidence-based skills and to sustain intervention effects while preserving the "low-touch" for scalable dissemination. Study design & methods: we now propose to conduct a multi-site trial of breeze+, which includes the two nurse-led breeze sessions, a booster session, and a digital health APP to reinforce home practice of the dyspnea management skills versus an enhanced usual care control condition (entailing educational resources on dyspnea management) in 420 patients with advanced lung cancer experiencing dyspnea. Massachusetts general hospital, johns hopkins university, and the university of miami will serve as study sites. The nurse-led sessions and digital health APP will be available in spanish and english to enable the recruitment of a diverse sample. We will centralize intervention delivery to facilitate implementation. The aims are to evaluate the effect of breeze+ on patient-reported dyspnea, physical function, quality of life, and coping with dyspnea. We also seek to identify critical facilitators and barriers of breeze+ adoption and implementation using the RE-aim (reach, effectiveness, adoption, implementation, maintenance) quest (qualitative evaluation for systematic translation) mixed methods framework. Conclusions: the proposed trial will lay the foundation to examine the intervention further for implementation and dissemination testing in diverse, real-world cancer care settings. If effective, breeze+ could also be adapted for other patients with advanced cancer and debilitating dyspnea.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of Miami | $122,272 |
Quick answers
Who received award R01CA292902?
R01CA292902 was awarded to The General Hospital Corporation by National Cancer Institute (National Institutes of Health) on July 7, 2026.
How much is award R01CA292902 worth?
$604,347 has been obligated on R01CA292902.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award